CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-CX-2009 Trial
28 Junio 2017 - 7:00AM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical
company developing investigational Probody™ therapeutics for the
treatment of cancer, today announced the treatment of the first
patient in the PROCLAIM
-CX-2009 study
(
Probody
Clinical
Assessment
In
Man), a Phase 1/2 clinical trial evaluating
CX-2009 as monotherapy in patients with select advanced solid
tumors. CX-2009 is a Probody drug conjugate (PDC) that targets
CD-166, an antigen that is broadly and highly expressed in many
types of cancers and is the first PDC to enter the clinic.
“The unique targeting ability of our Probody platform allows us
to pursue targets not accessible to conventional antibody drug
conjugates. With CX-2009, we are leveraging the high levels of
CD-166 on many types of cancer cells despite its presence on normal
tissue,” said Sean McCarthy, D.Phil., president and chief executive
officer of CytomX Therapeutics. “By targeting CD-166 and localizing
the activity of the CX-2009 Probody therapeutic to the tumor, we
could potentially treat a number of cancers for which few, if any,
treatment options exist.”
About CX-2009 and the PROCLAIM-CX-2009
TrialCX-2009, a PDC that targets cell surface protein
CD-166, is being developed for the treatment of solid tumors.
CD-166 is highly and homogeneously expressed on multiple tumor
types, such as breast cancer, endometrial cancer and prostate
cancer. CytomX has demonstrated that CD-166 effectively
internalizes antibody-drug conjugates resulting in potent cell
killing in-vitro. CX-2009 is designed to target CD-166 specifically
in the tumor microenvironment and deliver the tubulin-destabilizing
maytansine payload, DM4, to cancer cells. In 2014, CytomX entered
into a license agreement with ImmunoGen, Inc. to develop PDCs
against a defined number of targets, bringing together CytomX's
proprietary antibody masking technology and tumor-selective
protease substrates with ImmunoGen's highly potent antibody drug
conjugate cell-killing agents and engineered linkers. CX-2009 is
wholly owned by CytomX.
CX-2009 is being studied within PROCLAIM, CytomX’s international
modular umbrella clinical trial program that encompasses the Phase
1/2 development of multiple Probody therapeutics. PROCLAIM-CX-2009
is a dose-finding Phase 1/2 study evaluating CX-2009 as monotherapy
in patients with select cancer types, including non-small cell lung
cancer, breast cancer, ovarian cancer, endometrial cancer,
cholangiocarcinoma (bile duct cancer), head and neck cancer and
castration-resistant prostate cancer. The objectives of the study
are to establish the safety, tolerability, pharmacokinetics,
pharmacodynamics and preliminary antitumor activity of CX-2009.
More information about the trial is available at
ClinicalTrials.gov.
CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that are difficult to
predict, may be beyond our control, and may cause the actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied in such statements. Accordingly, you should not rely on any
of these forward-looking statements, including those relating to
the potential efficacy of CytomX’s product candidates, the
Company’s ability to develop and advance product candidates into
and successfully complete clinical trials, including the Company’s
Phase 1/2 clinical trial of CX-2009. Two of our product candidates
under our Probody platform are in the initial stages of clinical
development and our other product candidates are currently in
preclinical development, and the process by which preclinical and
clinical development could potentially lead to an approved product
is long and subject to significant risks and uncertainties.
Applicable risks and uncertainties include those relating to our
preclinical research and development, clinical development, and
other risks identified under the heading "Risk Factors" included in
the Company’s Quarterly Report on Form 10-Q filed with
the SEC on May 5, 2017. The forward-looking
statements contained in this press release are based on information
currently available to CytomX and speak only as of the date on
which they are made. CytomX does not undertake and specifically
disclaims any obligation to update any forward-looking statements,
whether as a result of any new information, future events, changed
circumstances or otherwise.
Media Contact:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388
Investor Contact:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
CytomX Therapeutics (NASDAQ:CTMX)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024